Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children’s Oncology Group

Kumar P, Willard VW, Embry L, Naranjo A, LaBarre B, Matthay KK, de Alarcon PA. Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2024 Jul;71(7):e31039. doi: 10.1002/pbc.31039. Epub 2024 Apr 30. PubMed PMID: 38689540; PubMed Central PMCID: PMC11116037.

This study aimed to describe long-term neurocognitive and adaptive functioning of patients with NA-OMAS treated with multi-modal therapy including intravenous immunoglobulin (IVIG) on Children’s Oncology Group (COG) protocol ANBL00P3.